{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:13Z","timestamp":1791945613293,"version":"4.3.4"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare and fatal disease of the pleural lining. Up to 80% of the MPM cases are linked to asbestos exposure. Even though its use has been banned in the industrialized countries, the cases continue to increase. MPM is a lethal cancer, with very little survival improvements in the last years, mirroring very limited therapeutic advances. Platinum-based chemotherapy in combination with pemetrexed and surgery are the standard of care, but prognosis is still unacceptably poor with median overall survival of approximately 12 months. The genomic landscape of MPM has been widely characterized showing a low mutational burden and the impairment of tumor suppressor genes. Among them, <jats:italic>BAP1<\/jats:italic> and <jats:italic>BLM<\/jats:italic> are present as a germline inactivation in a small subset of patients and increases predisposition to tumorigenesis. Other studies have demonstrated a high frequency of mutations in DNA repair genes. Many therapy approaches targeting these alterations have emerged and are under evaluation in the clinic. High-throughput technologies have allowed the detection of more complex molecular events, like chromotripsis and revealed different transcriptional programs for each histological subtype. Transcriptional analysis has also paved the way to the study of tumor-infiltrating cells, thus shedding lights on the crosstalk between tumor cells and the microenvironment. The tumor microenvironment of MPM is indeed crucial for the pathogenesis and outcome of this disease; it is characterized by an inflammatory response to asbestos exposure, involving a variety of chemokines and suppressive immune cells such as M2-like macrophages and regulatory T cells. Another important feature of MPM is the dysregulation of microRNA expression, being frequently linked to cancer development and drug resistance. This review will give a detailed overview of all the above mentioned features of MPM in order to improve the understanding of this disease and the development of new therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fonc.2021.660039","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T07:20:20Z","timestamp":1624432820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma"],"prefix":"10.3389","volume":"11","author":[{"given":"Stefanie","family":"Hiltbrunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela B.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Rigutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Laure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Lia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1743-8977-7-5","article-title":"Asbestos, Carbon Nanotubes and the Pleural Mesothelium: A Review of the Hypothesis Regarding the Role of Long Fibre Retention in the Parietal Pleura, Inflammation and Mesothelioma","volume":"7","author":"Donaldson","year":"2010","journal-title":"Part Fibre Toxicol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/019021400404528","article-title":"Asbestos Exposure Induces MCP-1 Secretion by Pleural Mesothelial Cells","volume":"26","author":"Tanaka","year":"2000","journal-title":"Exp Lung Res"},{"key":"B3","article-title":"Role of Oxyradicals in Mutagenicity and DNA Damage Induced by Crocidolite Asbestos in Mammalian Cells","volume":"59","author":"Xu","year":"1999","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2007622117","article-title":"Asbestos Induces Mesothelial Cell Transformation Via HMGB1-Driven Autophagy","volume":"117","author":"Xue","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3066","article-title":"Targeting Chromosomal Architectural HMGB Proteins Could be the Next Frontier in Cancer Therapy","volume":"80","author":"Mukherjee","year":"2020","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbagen.2016.09.031","article-title":"Quantitative Analysis of the Role of Fiber Length on Phagocytosis and Inflammatory Response by Alveolar Macrophages","volume":"1861","author":"Padmore","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2228","article-title":"A Role for the NLRP3 Inflammasome in Metabolic Diseases\u2013did Warburg Miss Inflammation","volume":"13","author":"Wen","year":"2012","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14523","article-title":"Tumor-Associated Macrophage-Derived Inflammatory Cytokine Enhances Malignant Potential of Malignant Pleural Mesothelioma","volume":"111","author":"Horio","year":"2020","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed Necrosis Induced by Asbestos in Human Mesothelial Cells Causes High-Mobility Group Box 1 Protein Release and Resultant Inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous Exposure to Chrysotile Asbestos Can Cause Transformation of Human Mesothelial Cells Via HMGB1 and TNF-\u03b1 Signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-Alpha Inhibits Asbestos-Induced Cytotoxicity Via a NF-KappaB-Dependent Pathway, A Possible Mechanism for Asbestos-Induced Oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.25.1.173","article-title":"Interleukin-1beta and Tumour Necrosis Factor-Alpha Promote the Transformation of Human Immortalised Mesothelial Cells by Erionite","volume":"25","author":"Wang","year":"2004","journal-title":"Int J Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the Effect of Immune Cells on the Outcome of Patients With Mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5804230","article-title":"Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types","volume":"2018","author":"Tazzari","year":"2018","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198687","article-title":"Innate or Adaptive Immunity? The Example of Natural Killer Cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4179","article-title":"Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma","volume":"71","author":"Platonova","year":"2011","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32363","article-title":"NK- and T-Cell Subsets in Malignant Mesothelioma Patients: Baseline Pattern and Changes in the Context of Anti-CTLA-4 Therapy","volume":"145","author":"Sottile","year":"2019","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/238431","article-title":"Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes Upon Asbestos Exposure and in Malignant Mesothelioma Patients","volume":"2015","author":"Nishimura","year":"2015","journal-title":"BioMed Res Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant Expression of TIM-3, LAG-3, PD-1 and PD-L1 as Immunotherapy Checkpoint Targets in Effusions of Mesothelioma Patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and Predictive Aspects of the Tumor Immune Microenvironment and Immune Checkpoints in Malignant Pleural Mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2016.04.015","article-title":"Precision Immunotherapy; Dynamics in the Cellular Profile of Pleural Effusions in Malignant Mesothelioma Patients","volume":"107","author":"Lievense","year":"2017","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32262","article-title":"Presence of Innate Lymphoid Cells in Pleural Effusions of Primary and Metastatic Tumors: Functional Analysis and Expression of PD-1 Receptor","volume":"145","author":"Tumino","year":"2019","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2438598","article-title":"Natural Killer Cells From Malignant Pleural Effusion Are Endowed With a Decidual-Like Proangiogenic Polarization","volume":"2018","author":"Bosi","year":"2018","journal-title":"J Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242783","article-title":"NK Cells From Malignant Pleural Effusions are Not Anergic But Produce Cytokines and Display Strong Antitumor Activity on Short-Term IL-2 Activation","volume":"43","author":"Vacca","year":"2013","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs005","article-title":"IL-2\/CD40-Driven NK Cells Install and Maintain Potency in the Anti-Mesothelioma Effector\/Memory Phase","volume":"24","author":"Jackaman","year":"2012","journal-title":"Int Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3328","article-title":"Recognition of CD1d-Restricted Antigens by Natural Killer T Cells","volume":"12","author":"Rossjohn","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The Biology of NKT Cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.20553","article-title":"Increased Frequency of Circulating Invariant Natural Killer T Cells in Malignant Pleural Mesothelioma Patients","volume":"13","author":"Altomare","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182a801f2","article-title":"Antitumor Impact of Interferon-\u03b3 Producing CD1d-Restricted NKT Cells in Murine Malignant Mesothelioma","volume":"36","author":"Tagawa","year":"2013","journal-title":"J Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1597-9","article-title":"Activation of CD1d-restricted Natural Killer T Cells can Inhibit Cancer Cell Proliferation During Chemotherapy by Promoting the Immune Responses in Murine Mesothelioma","volume":"63","author":"Wu","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26143","article-title":"Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic Value of the Lymphocyte-to-Monocyte Ratio and Other Inflammatory Markers in Malignant Pleural Mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ Health Prev Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00264-13","article-title":"Macrophage M1\/M2 Polarization Dynamically Adapts to Changes in Cytokine Microenvironments in Cryptococcus Neoformans Infection","volume":"4","author":"Davis","year":"2013","journal-title":"mBio"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80014-x","article-title":"Other Functions, Other Genes: Alternative Activation of Antigen-Presenting Cells","volume":"10","author":"Goerdt","year":"1999","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The Tumoral and Stromal Immune Microenvironment in Malignant Pleural Mesothelioma: A Comprehensive Analysis Reveals Prognostic Immune Markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111653","article-title":"TGF-\u03b2 Synergizes With Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth","volume":"209","author":"Fujii","year":"2012","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02759","article-title":"More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis","volume":"10","author":"Gschwandtner","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1186\/s12885-019-6419-1","article-title":"Serum Levels of the Chemokine CCL2 are Elevated in Malignant Pleural Mesothelioma Patients","volume":"19","author":"Kishimoto","year":"2019","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am J Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1309\/LN2075V7C8K31CH8","article-title":"Chemokine Receptors are Infrequently Expressed in Malignant and Benign Mesothelial Cells","volume":"127","author":"Davidson","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41598-017-18433-4","article-title":"IL-34 and CSF-1 Display an Equivalent Macrophage Differentiation Ability But a Different Polarization Potential","volume":"8","author":"Boulakirba","year":"2018","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural Effusions From Patients With Mesothelioma Induce Recruitment of Monocytes and Their Differentiation Into M2 Macrophages","volume":"11","author":"Ch\u00e9n\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e000182","DOI":"10.1136\/jitc-2019-000182","article-title":"Involvement of the M-CSF\/IL-34\/CSF-1R Pathway in Malignant Pleural Mesothelioma","volume":"8","author":"Blondy","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R Signaling Drives Mesothelioma Chemoresistance Via AKT Activation","volume":"5","author":"Cioce","year":"2014","journal-title":"Cell Death Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10561","article-title":"TGF-\u03b2 Induces M2-like Macrophage Polarization Via SNAIL-Mediated Suppression of a Pro-Inflammatory Phenotype","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.imbio.2015.11.016","article-title":"TGF-\u03b2 Signalling in Tumour Associated Macrophages","volume":"222","author":"Gratchev","year":"2017","journal-title":"Immunobiology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural Effusion of Patients With Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000180","article-title":"Differential Effects of Malignant Mesothelioma Cells on THP-1 Monocytes and Macrophages","volume":"34","author":"Izzi","year":"2009","journal-title":"Int J Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","article-title":"Tgf-\u03b2 Family Signaling in Tumor Suppression and Cancer Progression","volume":"9","author":"Seoane","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic Cytokines in Mesothelioma: A Study of VEGF, FGF-1 and -2, and TGF Beta Expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T Cells and Cytokines in Malignant Pleural Effusions Secondary to Mesothelioma and Carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06144.x","article-title":"Transforming Growth Factor-Beta 1 (TGF-Beta 1)- and Beta 2-Like Activities in Malignant Pleural Effusions Caused by Malignant Mesothelioma or Primary Lung Cancer","volume":"98","author":"Maeda","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-\u03b2 in Pleural Effusions for Diagnosis and Prognostic Stratification of Malignant Pleural Mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nri2528","article-title":"Trophic Macrophages in Development and Disease","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/path.1027","article-title":"The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/or.14.2.425","article-title":"Macrophage Infiltration and Its Prognostic Implications in Breast Cancer: The Relationship With VEGF Expression and Microvessel Density","volume":"14","author":"Tsutsui","year":"2005","journal-title":"Oncol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant Pleural Mesothelioma Immune Microenvironment and Checkpoint Expression: Correlation With Clinical-Pathological Features and Intratumor Heterogeneity Over Time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of Intratumoral Macrophage Phenotypes is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of Tumor-Infiltrating T Cells on Survival in Patients With Malignant Pleural Mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ Tumor-Infiltrating Lymphocytes Predict Favorable Prognosis in Malignant Pleural Mesothelioma After Resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the Immune Microenvironment in Malignant Pleural Mesothelioma Reveals Prognostic Subgroups of Patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/ijms19071881","article-title":"Experimental Model of Human Malignant Mesothelioma in Athymic Mice","volume":"19","author":"Colin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting Tumor-Associated Macrophages in An Orthotopic Murine Model of Diffuse Malignant Mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2905","article-title":"Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition","volume":"72","author":"Gao","year":"2012","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/vaccines4040036","article-title":"The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3757","article-title":"Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma Environment Comprises Cytokines and T-Regulatory Cells That Suppress Immune Responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08010183","article-title":"Production of Granulocyte Colony-Stimulating Factor by Malignant Mesothelioma","volume":"8","author":"Rikimaru","year":"1995","journal-title":"Eur Respir J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12140","article-title":"Granulocyte-Colony Stimulating Factor (G-CSF) Producing Malignant Pleural Mesothelioma: Report of a Case","volume":"6","author":"Fujiwara","year":"2015","journal-title":"Thorac Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1173299","article-title":"Murine Mesothelioma Induces Locally-Proliferating IL-10(+)TNF-\u03b1(+)CD206(-)CX3CR1(+) M3 Macrophages That Can Be Selectively Depleted by Chemotherapy or Immunotherapy","volume":"5","author":"Jackaman","year":"2016","journal-title":"Oncoimmunology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1004983","article-title":"Phenotype, Development, and Biological Function of Myeloid-Derived Suppressor Cells","volume":"5","author":"Zhao","year":"2016","journal-title":"Oncoimmunology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 Inhibition Improves Immunotherapy and is Associated With Decreased Numbers of Myeloid-Derived Suppressor Cells in Mesothelioma. Celecoxib Influences MDSC Function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The Immune Contexture in Human Tumours: Impact on Clinical Outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The Immune Microenvironment, Genome-Wide Copy Number Aberrations, and Survival in Mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T Cells and Immune Tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","article-title":"Prognostic Value of Tumor-Infiltrating FoxP3+ Regulatory T Cells in Cancers: A Systematic Review and Meta-Analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1360-z","article-title":"Peripheral CD8(+) T Cell Proliferation is Prognostic for Patients With Advanced Thoracic Malignancies","volume":"62","author":"McCoy","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.03.018","article-title":"Intra-Tumoural Regulatory T Cells: A Potential New Target in Cancer Immunotherapy","volume":"343","author":"Needham","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PloS One"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) Independently Predicts Shorter Survival in Malignant Pleural Mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum Pathol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25100","article-title":"Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 Expression in Malignant Pleural Mesothelioma is Associated With Sarcomatoid Histology and Poor Prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Single-Agent Chemotherapy for Advanced Pre-Treated Malignant Pleural Mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso Trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4883","article-title":"Role of Evaluating Tumor\u2212Infiltrating Lymphocytes, Programmed Death\u22121 Ligand 1 and Mismatch Repair Proteins Expression in Malignant Mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int J Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and Prognosis in Patients With Malignant Pleural Mesothelioma: A Meta-Analysis and Bioinformatics Study","volume":"12","author":"Jin","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant Mesothelioma Effusions Are Infiltrated By\u00a0CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells Within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s13104-018-3953-x","article-title":"Tumour Associated Lymphocytes in the Pleural Effusions of Patients With Mesothelioma Express High Levels of Inhibitory Receptors","volume":"11","author":"Chee","year":"2018","journal-title":"BMC Res Notes"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/cancers11121953","article-title":"Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is An Immune Checkpoint Molecule for Human T Cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710441105","article-title":"Programmed Death 1 Ligand Signaling Regulates the Generation of Adaptive Foxp3+CD4+ Regulatory T Cells","volume":"105","author":"Wang","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discovery"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-Domain Ig-containing Suppressor of T-Cell Activation (VISTA), a Potentially Targetable Immune Checkpoint Molecule, Is Highly Expressed in Epithelioid Malignant Pleural Mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod Pathol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1071-x","article-title":"Prognostic Impact of B-Cell Density in Cutaneous Melanoma","volume":"60","author":"Lad\u00e1nyi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0054","article-title":"Successful Combined Intratumoral Immunotherapy of Established Murine Mesotheliomas Requires B-cell Involvement","volume":"35","author":"Krishnan","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.88","article-title":"CD40-Activated B Cells Contribute to Mesothelioma Tumor Regression","volume":"89","author":"Jackaman","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01181.x","article-title":"Malignant Mesothelioma-Associated Antigens Recognized by Tumor-Infiltrating B Cells and the Clinical Significance of the Antibody Titers","volume":"100","author":"Shigematsu","year":"2009","journal-title":"Cancer Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/cancers12040915","article-title":"Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting","volume":"12","author":"Nicolini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B114","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1182\/asheducation-2016.1.293","article-title":"Introduction to Cancer Genetic Susceptibility Syndromes","volume":"2016","author":"McGee","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/cancers12041007","article-title":"Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, Atm, BAP1, and POT1","volume":"12","author":"Pastorino","year":"2020","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discovery"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-020-00157-6","article-title":"Functional Characterisation Guides Classification of Novel BAP1 Germline Variants","volume":"5","author":"Hong","year":"2020","journal-title":"NPJ Genomic Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to Asbestos Is Increased in Patients With Mesothelioma and Pathogenic Germline Variants in BAP1 or Other DNA Repair Genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"JCO2018790352","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019652117","article-title":"Heterozygous Germline BLM Mutations Increase Susceptibility to Asbestos and Mesothelioma","volume":"117","author":"Bononi","year":"2020","journal-title":"PNAS"},{"key":"B123","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-Art Strategies for Targeting the DNA Damage Response in Cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102101","article-title":"Is DNA Repair a Potential Target for Effective Therapies Against Malignant Mesothelioma","volume":"90","author":"Fuso Nerini","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.111","article-title":"Novel Germline Mutations in DNA Damage Repair in Patients With Malignant Pleural Mesotheliomas","volume":"15","author":"Guo","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 But Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-Methylguanine-DNA Methyltransferase Expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9058","article-title":"Safety and Efficacy of Tazemetostat, an Enhancer of Zeste-Homolog 2 Inhibitor, in Patients With Relapsed or Refractory Malignant Mesothelioma","volume":"38","author":"Zauderer","year":"2020","journal-title":"JCO"},{"key":"B129","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.3390\/ijms21239107","article-title":"The Crosstalk Between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication","volume":"21","author":"W\u00f6rthm\u00fcller","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3573","article-title":"Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup","volume":"26","author":"Pirker","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as Second- or Third-Line Palliative Therapy in Malignant Pleural Mesothelioma: An International, Multi-Centre, Single-Arm, Phase II Trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1856660","article-title":"The Role of BCL-2 Family Proteins and Therapeutic Potential of BH3-Mimetics in Malignant Pleural Mesothelioma","volume":"21","author":"Arulananda","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in Patients With Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01040-y","article-title":"Drug-Repositioning Screening Identified Fludarabine and Risedronic Acid as Potential Therapeutic Compounds for Malignant Pleural Mesothelioma","volume":"39","author":"Dell\u2019Anno","year":"2020","journal-title":"Invest New Drugs"},{"key":"B137","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","article-title":"Gene Expression Profiling of Homologous Recombination Repair Pathway Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma In Vitro","volume":"19","author":"Borchert","year":"2019","journal-title":"BMC Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520","article-title":"Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma Identifies Recurrent Mutations, Gene Fusions and Splicing Alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal Architecture in Mesothelioma Is Prognostic and Shapes the Tumour Microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B140","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-019-5652-y","article-title":"CDKN2A Copy Number and p16 Expression in Malignant Pleural Mesothelioma in Relation to Asbestos Exposure","volume":"19","author":"Kettunen","year":"2019","journal-title":"BMC Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular Characterization of Diffuse Malignant Peritoneal Mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Modern Pathol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"PO.19.00048","DOI":"10.1200\/PO.19.00048","article-title":"STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment","volume":"3","author":"R\u00fcschoff","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/cancers12092454","article-title":"Deep Sequencing Analysis Identified a Specific Subset of Mutations Distinctive of Biphasic Malignant Pleural Mesothelioma","volume":"12","author":"Torricelli","year":"2020","journal-title":"Cancers"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/cancers12102948","article-title":"Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase Ii RAMES Study","volume":"12","author":"Pagano","year":"2020","journal-title":"Cancers"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.002","article-title":"Genomic Analysis in Short- and Long-Term Patients With Malignant Pleura Mesothelioma Treated With Palliative Chemotherapy","volume":"132","author":"Torricelli","year":"2020","journal-title":"Eur J Cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.006","article-title":"Does Chromothripsis Make Mesothelioma an Immunogenic Cancer","volume":"14","author":"Carbone","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive Genomic Rearrangement Acquired in a Single Catastrophic Event During Cancer Development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/470476a","article-title":"Cancer: When Catastrophe Strikes a Cell","volume":"470","author":"Tubio","year":"2011","journal-title":"Nature"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/s41467-020-16134-7","article-title":"The Landscape of Chromothripsis Across Adult Cancer Types","volume":"11","author":"Voronina","year":"2020","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.12","article-title":"Chromosomal Rearrangements and Their Neoantigenic Potential in Mesothelioma","volume":"9","author":"Mansfield","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgz066","article-title":"Whole-Genome Sequencing of Human Malignant Mesothelioma Tumours and Cell Lines","volume":"40","author":"Oey","year":"2019","journal-title":"Carcinogenesis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03064-z","article-title":"Chromothripsis Drives the Evolution of Gene Amplification in Cancer","volume":"591","author":"Shoshani","year":"2020","journal-title":"Nature"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/ng.349","article-title":"Somatic Mutations of the Histone H3K27 Demethylase Gene UTX in Human Cancer","volume":"41","author":"van Haaften","year":"2009","journal-title":"Nat Genet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive Analysis of Chromothripsis in 2,658 Human Cancers Using Whole-Genome Sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat Genet"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The Molecular Basis of Malignant Pleural Mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac Surg Clin"},{"key":"B156","article-title":"The Novel Potent TEAD Inhibitor, K-975, Inhibits YAP1\/TAZ-TEAD Protein-Protein Interactions and Exerts an Anti-Tumor Effect on Malignant Pleural Mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"S1525-7304(20)30222-9","DOI":"10.1016\/j.cllc.2020.06.028","article-title":"Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II Atreus Study","author":"Cortinovis","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/md18120619","article-title":"Marine Anticancer Agents: An Overview With a Particular Focus on Their Chemical Classes","volume":"18","author":"Barreca","year":"2020","journal-title":"Mar Drugs"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in Cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Annu Rev Med"},{"key":"B160","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The Role of MicroRNAs in Human Cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242606799","article-title":"Frequent Deletions and Down-Regulation of Micro- RNA Genes miR15 and miR16 at 13q14 in Chronic Lymphocytic Leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.3.593","article-title":"Intercalating the Role of MicroRNAs in Cancer: As Enemy or Protector","volume":"21","author":"Behl","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"B163","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-00848-8","article-title":"The Role of Cancer-Derived microRNAs in Cancer Immune Escape","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","article-title":"The Role and Mechanisms of Action of microRNAs in Cancer Drug Resistance","volume":"11","author":"Si","year":"2019","journal-title":"Clin Epigenet"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.04.56","article-title":"MicroRNAs in Mesothelioma: From Tumour Suppressors and Biomarkers to Therapeutic Targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20409","article-title":"Targeting microRNA to Improve Diagnostic and Therapeutic Approaches for Malignant Mesothelioma","volume":"8","author":"Birnie","year":"2017","journal-title":"Oncotarget"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future","volume":"10","author":"Reid","year":"2020","journal-title":"Front Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN Are Dysregulated Among Other Genes by miRNAs in Malignant Mesothelioma -a miRNA Microarray Analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA Signature of Malignant Mesothelioma With Potential Diagnostic and Prognostic Implications","volume":"42","author":"Busacca","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.100354","article-title":"Pro-Tumorigenic Effects of miR-31 Loss in Mesothelioma","volume":"285","author":"Ivanov","year":"2010","journal-title":"J Biol Chem"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic Effects of mir-145 Loss in Malignant Pleural Mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"B173","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-Mesenchymal Transition in Malignant Mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod Pathol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring Expression of miR-16: A Novel Approach to Therapy for Malignant Pleural Mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0461LE","article-title":"A Significant Metabolic and Radiological Response After a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma","volume":"191","author":"Kao","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and Activity of microRNA-loaded Minicells in Patients With Recurrent Malignant Pleural Mesothelioma: A First-in-Man, Phase 1, Open-Label, Dose-Escalation Study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor Suppressor Micrornas Contribute to the Regulation of PD-L1 Expression in Malignant Pleural\u00a0Mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4346","article-title":"miR-193a-3p is a Potential Tumor Suppressor in Malignant Pleural Mesothelioma","volume":"6","author":"Williams","year":"2015","journal-title":"Oncotarget"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1186\/s12885-018-4801-z","article-title":"MiR-126 in Intestinal-Type Sinonasal Adenocarcinomas: Exosomal Transfer of MiR-126 Promotes Anti-Tumour Responses","volume":"18","author":"Tomasetti","year":"2018","journal-title":"BMC Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.02.009","article-title":"Clinical Significance of Circulating miR-126 Quantification in Malignant Mesothelioma Patients","volume":"45","author":"Tomasetti","year":"2012","journal-title":"Clin Biochem"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic Silencing of microRNA-34b\/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/52140","article-title":"Preclinical Evaluation of microRNA-34b\/c Delivery for Malignant Pleural Mesothelioma","volume":"68","author":"Ueno","year":"2014","journal-title":"Acta Med Okayama"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.05.020","article-title":"Microrna-215-5p Treatment Suppresses Mesothelioma Progression Via the MDM2-p53-Signaling Axis","volume":"27","author":"Singh","year":"2019","journal-title":"Mol Ther"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00446","article-title":"miR-182 and Mir-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma","volume":"8","author":"Suzuki","year":"2018","journal-title":"Front Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the Differential Diagnosis of Malignant Pleural Mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2010.090169","article-title":"A Diagnostic Assay Based on microRNA Expression Accurately Identifies Malignant Pleural Mesothelioma","volume":"12","author":"Benjamin","year":"2010","journal-title":"J Mol Diagn"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 With Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PloS One"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.03.002","article-title":"Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma","volume":"16","author":"Andersen","year":"2014","journal-title":"J Mol Diagn"},{"key":"B190","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12032-014-0303-2","article-title":"Upregulation of microRNA-31 Associates With a Poor Prognosis of Malignant Pleural Mesothelioma With Sarcomatoid Component","volume":"31","author":"Matsumoto","year":"2014","journal-title":"Med Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-score: A Novel 6-microRNA Signature That Predicts Survival Outcomes in Patients With Malignant Pleural Mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PloS One"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma\u2013A Pilot Study","volume":"7","author":"Weber","year":"2012","journal-title":"PloS One"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined Circulating Epigenetic Markers to Improve Mesothelin Performance in the Diagnosis of Malignant Mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9280170","article-title":"Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma","volume":"2017","author":"Weber","year":"2017","journal-title":"Dis Markers"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910393957","article-title":"DNA Methylation","volume":"2","author":"Jin","year":"2011","journal-title":"Genes Cancer"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.554570","article-title":"Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors\u2013Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment","volume":"10","author":"Yoshikawa","year":"2020","journal-title":"Front Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01126-z","article-title":"Targeting Epigenetics for Cancer Therapy","volume":"42","author":"Park","year":"2019","journal-title":"Arch Pharm Res"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00445","article-title":"Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and Critical Evaluation","volume":"10","author":"Ferrari","year":"2020","journal-title":"Front Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-019-0079-0","article-title":"Accumulation of Genetic and Epigenetic Alterations in Normal Cells and Cancer Risk","volume":"3","author":"Takeshima","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the Epigenome in Malignant Pleural Mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.014","article-title":"Noncanonical Pathway for Regulation of CCL2 Expression by An mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages","volume":"21","author":"Nakatsumi","year":"2017","journal-title":"Cell Rep"},{"key":"B205","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.3390\/cancers12113470","article-title":"Dna Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma","volume":"12","author":"Cugliari","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma From Lung Adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.3390\/ijms21176342","article-title":"Genomics and Functional Genomics of Malignant Pleural Mesothelioma","volume":"21","author":"Cakiroglu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70084-7","article-title":"A Lesson From Vorinostat in Pleural Mesothelioma","volume":"16","author":"Garassino","year":"2015","journal-title":"Lancet Oncol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.660039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T07:20:26Z","timestamp":1624432826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.660039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":209,"alternative-id":["10.3389\/fonc.2021.660039"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.660039","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"article-number":"660039"}}